

# Giovani Triolo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5778182/publications.pdf>

Version: 2024-02-01

55  
papers

2,873  
citations

186209

28  
h-index

168321

53  
g-index

55  
all docs

55  
docs citations

55  
times ranked

3844  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjögren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. <i>Clinical and Experimental Immunology</i> , 2015, 181, 219-229.	1.1	38
2	Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 $\beta$ via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3 (NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. <i>Clinical and Experimental Immunology</i> , 2015, 182, 35-44.	1.1	100
3	Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis. <i>Genes and Immunity</i> , 2015, 16, 35-42.	2.2	29
4	Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 686-691.	2.9	340
5	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. <i>Autoimmunity Reviews</i> , 2015, 14, 429-437.	2.5	46
6	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. <i>Cytotherapy</i> , 2015, 17, 832-849.	0.3	19
7	Interleukin-36 axis is modulated in patients with primary Sjögren's syndrome. <i>Clinical and Experimental Immunology</i> , 2015, 181, 230-238.	1.1	95
8	Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1739-1747.	0.5	236
9	The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-10 producing Th17 lymphocytes in patients with early rheumatoid arthritis. <i>Rheumatology International</i> , 2015, 35, 171-175.	1.5	33
10	Response to: IL-23 expression and activation of autophagy in synovium and PBMCs of HLA-B27 positive patients with ankylosing spondylitis by Neerincx et al.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e69-e69.	0.5	1
11	The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 533-541.	1.3	22
12	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	0.8	21
13	Rituximab in primary Sjögren's syndrome: a ten-year journey. <i>Lupus</i> , 2014, 23, 1337-1349.	0.8	21
14	Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1566-1574.	0.5	145
15	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 314-324.	1.6	61
16	Pathological Implications of Th1/Th2 Cytokine Genetic Variants in Behçet's Disease: Data from a Pilot Study in a Sicilian Population. <i>Biochemical Genetics</i> , 2013, 51, 967-975.	0.8	12
17	IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 258-264.	0.5	55
18	Jejunioileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 441-452.	1.3	18

#	ARTICLE	IF	CITATIONS
19	Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 782-783.	0.5	29
20	Longterm Retention of Tumor Necrosis Factor- $\alpha$ Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. <i>Journal of Rheumatology</i> , 2012, 39, 1179-1184.	1.0	87
21	Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 295-301.	0.5	143
22	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	2.5	146
23	Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1869-1878.	6.7	111
24	One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. <i>Rheumatology International</i> , 2011, 31, 33-37.	1.5	67
25	Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2097-2104.	6.7	31
26	A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. <i>Rheumatology International</i> , 2010, 30, 1437-1440.	1.5	41
27	Expansion of intestinal CD4+CD25 <sup>high</sup> Treg cells in patients with ankylosing spondylitis: A putative role for interleukin-10 in preventing intestinal Th17 response. <i>Arthritis and Rheumatism</i> , 2010, 62, 3625-3634.	6.7	53
28	HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities. <i>Radiologia Medica</i> , 2009, 114, 190-203.	4.7	30
29	Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis. <i>Rheumatology International</i> , 2009, 30, 193-198.	1.5	33
30	Alterations of the Beneficial Effect of Deep Inspiration in Scleroderma: Relationships between Lung Function and Imaging. <i>Respiration</i> , 2008, 76, 303-310.	1.2	1
31	Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1210-1215.	0.5	25
32	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 249-252.	0.5	46
33	NF- $\kappa$ B protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. <i>Arthritis and Rheumatism</i> , 2005, 52, 2179-2191.	6.7	59
34	IVIg in APS pregnancy. <i>Lupus</i> , 2004, 13, 731-735.	0.8	23
35	Cognitive impairment in Behçet's disease patients without overt neurological involvement. <i>Journal of the Neurological Sciences</i> , 2004, 220, 99-104.	0.3	62
36	Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2003, 48, 728-731.	6.7	206

#	ARTICLE	IF	CITATIONS
37	Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 999-1004.	1.5	11
38	Pathogenesis of autoimmune diseases associated with 8.1Â ancestral haplotype: a genetically determined defect of C4 influences immunological parameters of healthy carriers of the haplotype. <i>Biomedicine and Pharmacotherapy</i> , 2003, 57, 274-277.	2.5	43
39	Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 280-281.	0.5	62
40	Prevalence of headache in patients with Behcet's disease without overt neurological involvement. <i>Cephalalgia</i> , 2003, 23, 105-108.	1.8	26
41	Humoral and cell mediated immune response to cow's milk proteins in Behcet's disease. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 459-462.	0.5	18
42	Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 560-561.	0.5	60
43	Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells. <i>Diabetologia</i> , 2000, 43, 1039-1047.	2.9	27
44	Enhancement of Endothelial Cell E-Selectin Expression by Sera from Patients with Active Behçet's Disease: Moderate Correlation with Anti-endothelial Cell Antibodies and Serum Myeloperoxidase Levels. <i>Clinical Immunology</i> , 1999, 91, 330-337.	1.4	50
45	IgG anti-endothelial cell antibodies (AECA) in type I diabetes mellitus; induction of adhesion molecule expression in cultured endothelial cells. <i>Clinical and Experimental Immunology</i> , 1998, 111, 491-496.	1.1	11
46	Anti-single-stranded DNA antibody in the sera of patients with type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 1997, 34, 39-41.	1.2	6
47	Detection of anti-myeloperoxidase antibodies in the serum of patients with type 1 diabetes mellitus. <i>Acta Diabetologica</i> , 1996, 33, 103-107.	1.2	3
48	Inhibition of FcÎ³ Receptors in the Plasma of Subjects with Down's Syndrome. <i>Clinical Immunology and Immunopathology</i> , 1993, 69, 92-96.	2.1	2
49	Two-site ELISA for quantification of the terminal C5b-9 complement complex in plasma. <i>Journal of Immunological Methods</i> , 1993, 163, 169-172.	0.6	4
50	Phosphatidylserine counteracts physiological and pharmacological suppression of humoral immune response. <i>Immunopharmacology</i> , 1990, 19, 185-195.	2.0	7
51	Immune complex-mediated inhibition of lymphocyte FcÎ³ receptors in the plasma of patients with type 1 (insulin-dependent) diabetes mellitus: Association with anti-ssDNA antibodies. <i>Clinical Immunology and Immunopathology</i> , 1990, 54, 228-236.	2.1	5
52	IgA- and insulin-containing (C3-fixing) circulating immune complexes in diabetes mellitus. <i>Clinical Immunology and Immunopathology</i> , 1984, 30, 169-177.	2.1	36
53	Normal plasma thromboxane B2 (TXB2) and 6-keto-PGF1± levels in childhood diabetes. <i>Prostaglandins, Leukotrienes, and Medicine</i> , 1983, 12, 437-438.	0.8	2
54	Platelet thromboxane synthesis in treated childhood diabetes mellitus. <i>Thrombosis Research</i> , 1983, 32, 469-477.	0.8	5

#	ARTICLE	IF	CITATIONS
55	Detection and characterization of antibodies to polymerized human serum albumin (AAA) by ELISA. Journal of Immunological Methods, 1983, 62, 257-263.	0.6	10